Erythromycin treatment is beneficial for longstanding Moraxella catarrhalis associated cough in children

Scand J Infect Dis. 1993;25(3):323-9. doi: 10.3109/00365549309008506.

Abstract

The benefits of antibiotic treatment and a nasopharyngeal culture in children with longstanding cough were analysed in a prospective randomized open study. Clinically suspected pertussis was excluded. Of 40 children given erythromycin for 7 days, 35 (88%) recovered in one week, compared with 17/47 (36%) untreated (p < 0.0001). Erythromycin eliminated Moraxella catarrhalis from the nasopharynx in 21/31 children (68%), compared with spontaneous disappearance in 7/35 (20%) untreated controls (p < 0.001). Purulent bronchitis or otitis media occurred in 2 children (5%) in the treatment group and in 21 (45%) in the control group (p < 0.01). To evaluate the clinical role of isolated pathogens, the 47 untreated subjects were studied. Seven of 35 children harbouring M. catarrhalis recovered, compared with 8/12 in whom this bacterium was absent (p < 0.01). No correlation was found between the isolation of Haemophilus influenzae or Streptococcus pneumoniae and the clinical outcome. Children with persistent cough > 10 days may benefit from erythromycin treatment. M. catarrhalis in the nasopharynx indicates prolonged symptoms and increased risk of bacterial complications.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Child
  • Child, Preschool
  • Cough / drug therapy*
  • Cough / microbiology
  • Erythromycin / pharmacology
  • Erythromycin / therapeutic use*
  • Humans
  • Infant
  • Moraxella catarrhalis / drug effects*
  • Moraxella catarrhalis / isolation & purification
  • Nasopharynx / microbiology
  • Neisseriaceae Infections / drug therapy*
  • Neisseriaceae Infections / microbiology
  • Prospective Studies
  • Surveys and Questionnaires
  • Time Factors

Substances

  • Erythromycin